Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Leventi1,2, A. Aksan2,3*, J. Stein1,2, K. Farrag1,2

1DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 2Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 3Hacettepe University, Faculty of Health Sciences, Ankara, Turkey

P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patientsECCO '18 Vienna
Year: 2018
Authors:

N. Daferera1*, S. Ignatova2, A. Münch3

1Department of Gastroenterology and Hepatology, Linköping, Sweden, 2Department of Pathology, Linköping, Sweden, 3Department of Gastroenterology and Hepatology, Linköping, Sweden

P618: Post-operative pain following laparoscopic right hemicolectomy for Crohn’s disease a comparative studyECCO '18 Vienna
Year: 2018
Authors:

K. McKevitt*, S. Galvin, J. Burke

Beaumont Hospital, Colorectal and General Surgery, Dublin, Ireland

P619: Systematic review: Psychosocial factors associated with pain in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

L. Sweeney1*, W. Czuber-Dochan1, R. Moss-Morris2, G. Chumbley3, L. Meade4, C. Norton1

1King's College London, Faculty of Nursing and Midwifery and Palliative Care, London, UK, 2King's College London, Health Psychology Section, London, UK, 3Imperial College Healthcare NHS Trust, Pain Service, London, UK, 4King's College London, Faculty of Life Sciences and Medicine, London, UK

P620: Golimumab in ulcerative colitis: A multi-centre real-world experienceECCO '18 Vienna
Year: 2018
Authors:

A. Kumar1*, J. Slater1, J. Jones1, T. Troth2, G. Baker3, M. Love4, J. Nahal5, D. Rattehalli1

1Russells Hall Hospital, Gastroenterology, Birmingham, UK, 2Solihull Hospital, Gastroenterology, Birmingham, UK, 3New Cross Hospital, Gastroenterology, Birmingham, UK, 4Queen Elizabeth Hospital, Gastroenterology, Birmingham, UK, 5Walsall Manor Hospital, Gastroenterology, Birmingham, UK

P621: Faecal calprotectin after the induction of anti-TNF therapy predicts mucosal healing in patients with ulcerative colitis: A prospective single-centre studyECCO '18 Vienna
Year: 2018
Authors:

L. Bertani1*, N. de Bortoli1, L. Ceccarelli2, G. Mumolo2, G. Tapete1, E. Albano1, G. Laino1, G. Di Fluri2, M. Bellini2, A. Ricchiuti2, S. Marchi1, F. Costa2

1University of Pisa, New Technologies and Translational Medicine, Pisa, Italy, 2Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy

P622: Surgery for severely active ulcerative colitis in the era of new medical treatment: The impacts of medications on surgery avoidance, and short-term and long-term surgical outcomesECCO '18 Vienna
Year: 2018
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P623: Quality of life as predictor of biological levels decay in inflammatory bowel diseasesECCO '18 Vienna
Year: 2018
Authors:

D. Ceballos1*, M.D. Fiuza2, I. Alarcón3

1Hospital Universitario de Gran Canaria Dr. Negrin, Gastroenterology, Las Palmas, Spain, 2Hospital Universitario de Gran Canaria Dr. Negrin, Investigation Unit, Las Palmas, Spain, 3Hospital Universitario de Gran Canaria Dr. Negrin, Clinical Analisys Laboratory, Las Palmas, Spain

P624: Vedolizumab can induce clinical remission in patients with chronic antibiotic-refractory pouchitis: A retrospective single-centre experienceECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, C. Claeys1, G. Van Assche1,2, A. D'Hoore3, A. Wolthuis3, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3University Hospitals Leuven, Dpt. Abdominal Surgery, Leuven, Belgium

P625: A prospective study to assess the effectiveness of tacrolimus therapy in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

M. Kishi*, F. Hirai, N. Takatsu, Y. Takada, Y. Yutaka, T. Takeda, K. Yao, T. Matsui, T. Ueki

Fukuoka University Chikushi Hospital, Chikushino, Japan

P626: Development of a model of 3D imaging for the pre-operative planning of TaTMEECCO '18 Vienna
Year: 2018
Authors:

K. Sahnan1*, G. Pellino2, S.O. Adegbola1, P.J. Tozer1, P. Chandrasinghe3, D. Misovikc1, R. Hompes4, A.L. Hart5, J. Warusavitarne1, P.F. Lung6

1St Mark's Hospital, Colorectal Surgery, London, UK, 2Università della Campania “Luigi Vanvitelli”, Naples, Italy, 3University of Kelaniya, Kelaniya, Sri Lanka, 4Academic Medical Center (AMC) University of Amsterdam, Amsterdam, The Netherlands, 5St Mark's Hospital, IBD/Physiology, London, UK, 6St Mark's Hospital, Gastrointestinal Imaging, London, UK

P627: Audit of the assessment, prevalence and treatment of osteoporosis in a single-centre cohort of patients with inflammatory bowel disease managed with tumour necrosis factor inhibitor treatmentECCO '18 Vienna
Year: 2018
Authors:

O. Cronin*, S. Bell

St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia

P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiencesECCO '18 Vienna
Year: 2018
Authors:

K. Szántó1*, K. Farkas1, M. Rutka1, A. Bálint1, R. Bor1, Á. Milassin1, A. Fábián1, Z. Szepes1, F. Nagy1, N. Vass2, D. Szűcs2, T. Molnár1

1University of Szeged, 1st Department of Internal Medicine, Szeged, Hungary, 2University of Szeged, Department of Pediatrics, Szeged, Hungary

P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-upECCO '18 Vienna
Year: 2018
Authors:

S. D'Ugo1,2*, F. Romano2, G. Bagaglini2, L. Fazzolari2, B. Sensi2, A. Di Giorgio2, G. Sica2

1Tor Vergata University, Surgery, Rome, Italy, 2Tor Vergata University, Department of Surgery, Rome, Italy

P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximabECCO '18 Vienna
Year: 2018
Authors:

G. Noguier*, C. Montaillier, L. Colombeau, T. Ticaud, E. Parussini

Theradiag, R&D, Croissy Beaubourg, France

P631: Treatment of established post-operative recurrence of Crohn’s disease with anti-TNF agents: Preliminary data of a multicentre, nationwide studyECCO '18 Vienna
Year: 2018
Authors:

F. Cañete1,2*, M. Mañosa2,3, M. Barreiro-de Acosta4, E. Iglesias5, R. Ríos6, R.C. González-Sueyro7, A. Villoria3,8, M. Navarro-Llavat9, I. Rodriguez-Lago10, C. Taxonera11, P. Navarro12, P. López13, L. Ramos14, M. Van Domselaar15, A. Algaba16, M.J. Casanova3,17, C. Muñoz-Villafranca18, R. Pajares19, M. Sampedro20, M. Rivero21, P.G. Delgado-Guillena22, A. Hernández23, C. Aràjol24, A.F. Pordomingo25, M. Piqueras26, E. Sáinz-Arnau27, O. Benítez-Leiva3,28, P. Ramírez-de la Piscina29, E. Cabré2,3, E. Domènech2,3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona - Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Department of Gastroenterology, Badalona - Barcelona, Spain, 3CIBEREHD, Madrid, Spain, 4CHU Santiago, Santiago de Compostela, Spain, 5Hospital Reina Sofía, Cordoba, Spain, 6Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 7Hospital Universitari Clínic, Gastroenterology, Barcelona, Spain, 8Hospital Parc Taulí, Gastroenterology, Sabadell, Spain, 9Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain, 10Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 11Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 12Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, 13Hospital Universitario Fundación Alcorcón, Gastroenterology, Alcorcón, Spain, 14Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain, 15Hospital Universitario de Torrejón, Gastroenterology, Torrejón de Ardoz, Spain, 16Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, 17Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 18Hospital Universitario Basurto, Gastroenterology, Bilbao, Spain, 19Hospital Universitario Infanta Sofía, Gastroenterology, San Sebastián de los Reyes, Spain, 20Hospital de Mataró, Gastroenterology, Mataró, Spain, 21Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain, 22Hospital General de Granollers, Gastroenterology, Granollers, Spain, 23Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, 24Hospital Universitari de Bellvitge; IDIBELL, Gastroenterology, L'Hospitalet del Llobregat, Spain, 25Hospital Universitario de Salamanca, Gastroenterology, Salamanca, Spain, 26Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain, 27Hospital Arnau de Vilanova, Gastroenterology, Lleida, Spain, 28Hospital Universitario Mútua Terrassa, Gastroenterology, Terrassa, Spain, 29Hospital Universitario Araba, Gastroenterology, Vitoria, Spain

P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S. Stefanovic1*, I. Detrez2, G. Compernolle2, E. Brouwers2, N. Sever1, B. Stabuc1, I. Ferkolj1, N. Smrekar1, G. Novak1, M. Kozelj1, M. Ferrante3, A. Gils2, D. Drobne1

1University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia, 2Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

P633: Concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn’s disease: Results from FITZROY studyECCO '18 Vienna
Year: 2018
Authors:

W. Reinisch1*, G. De Hertogh2, G. D'Haens3, W. Li4, A. Serone4, C. Tasset5, A. Van der Aa5, S. Vermeire6

1Medical University of Vienna, Division of Gastroenterology and Hepatology, Vienna, Austria, 2University Hospitals Leuven, Department of Pathology, Leuven, Belgium, 3Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands, 4Gilead Sciences, Inc., Foster City, USA, 5Galapagos NV, Mechelen, Belgium, 6University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium

P634: Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

A. Almutairdi, C. Ma*, P.G. Kotze, A. Al-Damarki, S. Devlin, G. Kaplan, C. Seow, K. Novak, C. Lu, J. Ferraz, M. Stewart, M. Buresi, M. Mathivanan, H. Jijon, J. Heatherington, M.-L. Martin, R. Panaccione

University of Calgary, IBD unit, division of Gastroenterology and Hepatology, Calgary, Canada

P635: Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in GermanyECCO '18 Vienna
Year: 2018
Authors:

A. Groth1, T. Wilke2, A. Brandes3*, B. Ratsch3, A. Fuchs4, B. Deiters5, B. Bokemeyer6

1IPAM e.V., Wismar, Germany, 2Ingress Health HWM GmbH, Wismar, Germany, 3Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany, 4AOK Plus, Dresden, Germany, 5GWQ Serviceplus AG, Düsseldorf, Germany, 6Gastroenterologische Gemeinschaftspraxis Minden, Minden, Germany